Related Experiment Video
Updated: Jan 7, 2026

Comparing the Effects of Electronic Cigarette Vapor and Cigarette Smoke in a Novel In Vivo Exposure System
Published on: May 24, 2017
Recent trends in sales of electronic nicotine devices and oral nicotine pouches by flavour
Clinton H Durney1, Rafael Meza2,3,4, Evelyn Jimenez-Mendoza5
1Department of Population Health Sciences, British Columbia Cancer Research Institute, Vancouver, British Columbia, Canada cdurney@bccrc.ca.
Background:
The landscape of tobacco and nicotine delivery products has rapidly evolved with the introduction of electronic nicotine delivery systems (ENDSs) and oral nicotine pouches (ONPs). Understanding sales trends and flavour preferences is critical for assessing these products' public health impact and informing regulatory strategies.
Objective:
To characterise recent trends in US sales of ENDS and ONPs from 2018 to 2023, overall and by flavour.
Methods:
Information Resources retail sales data covering 40 states from 7 January 2018 to 16 July 2023, were used to document trends in ENDS and ONP sales from brick-and-mortar retailers, by product flavour (non-menthol, mint/menthol and tobacco/unflavoured) in 4 week periods.
Results:
ENDS and ONP sales have shown significant growth, with notable fluctuations coinciding with public health concerns and regulatory announcements. Specifically, non-menthol flavoured ENDS initially experienced a decline in sales following regulatory actions in early 2020 but strongly rebounded thereafter. Meanwhile, ONP sales have increased steadily, dominated by mint/menthol flavours. These trends may reflect consumer flavour preferences as well as manufacturers' strategic responses to policy changes. Sensitivity analyses using more recent sales data from 24 states confirm that these patterns persist.
Conclusions:
Differences in ENDS and ONP sales trends by flavour type underscore the importance of ongoing, detailed monitoring of nicotine product sales and use, to clarify public health implications and guide regulation. Given the growing variety of nicotine and tobacco products available today, tobacco regulatory frameworks must consider trends across this rapidly evolving market to understand and mitigate associated public health risks.
More Related Videos
09:30A Microcontroller Operated Device for the Generation of Liquid Extracts from Conventional Cigarette Smoke and Electronic Cigarette Aerosol
Published on: January 18, 2018
08:39Generation of Electronic Cigarette Aerosol by a Third-Generation Machine-Vaping Device: Application to Toxicological Studies
Published on: August 25, 2018
Related Concept Videos
Stimulants
Cocaine can be administered via snorting, injection, or smoking. It primarily functions by blocking the reuptake of dopamine, resulting in a euphoric high characterized by an intense sensation of happiness and...
Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
Drug Delivery: Miscellaneous Routes
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
Inhaled Medications
Gustation
Taste Buds and Receptors